EpiVax, Inc. - Informatics and Immunology
  • Our Company
    • Company Overview
    • Corporate Responsibility
    • Mission, Vision & Values
    • Team
    • Careers
    • Contact Us
  • Pipeline
    • Pipeline Overview
    • BioDefense Vaccines
    • Tregitope: Immunomodulation Power Tool
    • Deimmunization Projects
  • Vaccine Services
    • Vaccine Services
    • iVAX: Web-based Vaccine Design
    • PreVAX Analysis
    • EpiCC
  • Immunogenicity Assessment
    • Immunogenicity Assessment Overview
    • ISPRI Web-based Immunogenicity Assessment
    • PreDeFT Analysis
    • High Throughput Immunogenicity Analysis
    • PANDA Screening
    • ISPRI for Host Cell Proteins
    • Deimmunization
    • Trusted Expert Advice (TEA) Consulting Services
  • Lab Services
    • Lab Services Overview
    • HLA Binding Assays
    • T Cell Assays
  • Press Room
    • Press Room
    • Events
      • Webinars
    • Publication & Poster Search
    • Client Testimonials
    • Thinking Out Loud (Blog)
    • Recipes For Success (Podcast)
  • Contact Us
Select Page
Evaluating Immunogenicity Risk Due to Host Cell Protein Impurities in Antibody-Based Biotherapeutics

Evaluating Immunogenicity Risk Due to Host Cell Protein Impurities in Antibody-Based Biotherapeutics

by Sarah Moniz | Dec 22, 2017

Improved Personalized Vaccine and Adoptive Cell Transfer Immunotherapy Design by Immunoinformatic Analysis of Cancer Neo-epitopes

Improved Personalized Vaccine and Adoptive Cell Transfer Immunotherapy Design by Immunoinformatic Analysis of Cancer Neo-epitopes

by epivax3 | Oct 21, 2016

High-Value T Cell Epitope Selection for Mutanome-Directed Cancer Immunotherapy Using an Innovative Cancer Neo-Epitope Classification System

High-Value T Cell Epitope Selection for Mutanome-Directed Cancer Immunotherapy Using an Innovative Cancer Neo-Epitope Classification System

by epivax3 | Oct 21, 2016

Immunogenicity Analysis of Chinese Hamster Ovary (CHO) Host Cell Protein Contaminants in Therapeutic Protein Formulations

Immunogenicity Analysis of Chinese Hamster Ovary (CHO) Host Cell Protein Contaminants in Therapeutic Protein Formulations

by epivax3 | Oct 21, 2016

The ISPRI Toolkit Rapidly Screens Biologic Product Candidates for Immunogenic Potential Driven by T cell Epitope Content and Foreignness

The ISPRI Toolkit Rapidly Screens Biologic Product Candidates for Immunogenic Potential Driven by T cell Epitope Content and Foreignness

by epivax3 | Oct 21, 2016

« Older Entries

Recent Posts

  • Dreaming of Peptides (and Hello from Tokyo!)
  • Streamlining Generic Drug Immunogenicity Evaluation: EpiVax’s “PANDA” Approach
  • Throw Down a Challenge
  • EpiVax Birthday Cake Alert! | Fall ’23 Travel Schedule
  • Lab Day at the Beach 2023 *Pictures!*

Categories

  • EpiVax Immunoncology
  • Events
  • Featured
  • News
  • Recipes for Success – Vlog
  • Thinking Out Loud -Blog
  • Uncategorized
  • Webinars

Discover

  • Vaccine Services
  • Immunogenicity Assessment
  • Deimmunization
  • Lab Services
  • Pipeline

About

  • Our Company
  • Press Room
  • Events
  • Publication & Poster Search
  • Thinking Out Loud (Blog)
  • Contact Us

Connect

© 2023 EpiVax, Inc. – Informatics and Immunology, All rights reserved. Privacy Policy • 188 Valley Street, Suite 424, Providence, RI 02909 • ph: 401.272.2123 • fax: 401.272.7562